GlassScriptPhysician profile
Adriana Mccutcheon
NPI 1558018176
$4,675.67
in general payments reported to CMS, 2019-2025
29 companies · $906 in 2025
The $906 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $627 · 2023: $1,685 · 2024: $1,458 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,041 · Travel and Lodging: $7.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,041.44 |
| Travel and Lodging | $7.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $700.19 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $516.71 | 2022-2025 | Verquvo, Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.33 | 2022-2025 | Jardiance |
| Pfizer INC. | $379.90 | 2023-2025 | |
| Boston Scientific Corporation | $327.52 | 2022-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Atricure, INC. | $270.52 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $207.63 | 2022-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $203.87 | 2022-2024 | Xarelto |
| Amgen INC. | $184.75 | 2023-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $168.72 | 2022-2025 | |
| Abiomed | $132.70 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $129.06 | 2024 | Arcalyst |
| Cvrx, INC. | $129.04 | 2023-2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $115.86 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $106.15 | 2023 | Optimizer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $105.98 | 2022-2025 | Wainua, Brilinta, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.46 | 2023-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $73.35 | 2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $48.18 | 2025 | Wegovy, Ozempic |
| Bridgebio Pharma, INC. | $43.40 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $41.31 | 2024-2025 | Inspire |
| Heartflow, INC. | $35.29 | 2023 | Ffrct |
| Medtronic, INC. | $32.10 | 2022-2023 | Venaseal |
| Resmed Corp | $30.02 | 2022 | |
| Sanofi-Aventis U.S. LLC | $25.31 | 2024 | |
| Alnylam Pharmaceuticals INC. | $24.74 | 2022 | |
| Edwards Lifesciences Corporation | $23.91 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kiniksa Pharmaceuticals, LTD. | $18.57 | 2023 | Arcalyst |
| Vivaquant INC, Dba Rhythm Express | $5.10 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriana Mccutcheon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.